The DOI matches its Crossref record; 16 of the 16 references it cites were found in a registry or an index.
Increased risk of coccidioidomycosis in patients treated with tumor necrosis factor α antagonists
Abstract
Objective: To describe a group of patients who were treated with tumor necrosis factor α (TNFα) antagonists and who developed coccidioidomycosis, and to test the hypothesis that patients with inflammatory arthritis receiving TNFα antagonist therapy are at higher risk for developing symptomatic coccidioidomycosis. Methods: Cases of coccidioidomycosis were identified and reviewed from among patients receiving TNFα antagonist therapy from May 1998 through February 2003 in 5 practices within the areas endemic for coccidioidomycosis (Arizona, California, and Nevada). In addition, the relative risk of developing symptomatic coccidioidomycosis was calculated in patients with inflammatory arthritis who were receiving treatment with infliximab, in comparison with patients with inflammatory arthritis who were not receiving infliximab, from January 2000 to February 2003 in a single medical center. Results: Thirteen cases of documented coccidioidomycosis were associated with TNFα antagonist therapy. Twelve cases were associated with the use of infliximab and 1 case with etanercept. Among the cohort of patients from a single medical center, 7 of the 247 patients receiving infliximab and 4 of the 738 patients receiving other therapies developed symptomatic coccidioidomycosis (relative risk 5.23, 95% confidence interval 1.54–17.71; P < 0.01). Conclusion: Patients with inflammatory arthritis who are undergoing treatment with infliximab appear to be at higher risk for developing symptomatic coccidioidomycosis as compared with those not receiving infliximab.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Tuberculosis Associated with Infliximab, a Tumor Necrosis Factor α–Neutralizing Agent
Keane, J., Gershon, S., Wise, R. P., Mirabile-Levens, E., Kasznica, J., Schwieterman, W. D., Siegel, J. N., & Braun, M. M. (2001) · New England Journal of Medicine · doi:10.1056/nejmoa011110 · Cited by 3,710
Gardam, M. A., Keystone, E. C., Menzies, R., Manners, S., Skamene, E., Long, R., & Vinh, D. C. (2003) · The Lancet Infectious Diseases · doi:10.1016/s1473-3099(03)00545-0 · Cited by 752
Lee, J., Slifman, N. R., Gershon, S. K., Edwards, E. T., Schwieterman, W. D., Siegel, J. N., Wise, R. P., Brown, S. L., Udall, J. N., & Braun, M. M. (2002) · Arthritis & Rheumatism · doi:10.1002/art.10583 · Cited by 443
Serology of coccidioidomycosis
Pappagianis, D., & Zimmer, B. L. (1990) · Clinical Microbiology Reviews · doi:10.1128/cmr.3.3.247 · Cited by 382
PATTERN OF 39,500 SEROLOGIC TESTS IN COCCIDIOIDOMYCOSIS
Smith, C. E. (1956) · Journal of the American Medical Association · doi:10.1001/jama.1956.02960420026008 · Cited by 281
Coccidioidomycosis in Solid Organ Transplantation
Blair, J. E., & Logan, J. L. (2001) · Clinical Infectious Diseases · doi:10.1086/323463 · Cited by 213
Drutz, D. J., & Catanzaro, A. (1978) · PubMed · doi:10.1164/arrd.1978.117.3.559 · Cited by 176
Ampel, N. M., Dols, C. L., & Galgiani, J. N. (1993) · The American Journal of Medicine · doi:10.1016/0002-9343(93)90054-s · Cited by 170
Self-citationCoccidioidomycosis in renal replacement therapy
Cohen, I. M. (1982) · Archives of Internal Medicine · doi:10.1001/archinte.1982.00340160069017 · Cited by 163
Infection complications associated with the use of biologic agents
Bresnihan, B., & Cunnane, G. (2003) · Rheumatic Disease Clinics of North America · doi:10.1016/s0889-857x(02)00101-1 · Cited by 119
Cited by
Epidemiology of Invasive Mycoses in North America
Pfaller, M. A., & Diekema, D. J. (2010) · Critical Reviews in Microbiology · doi:10.3109/10408410903241444 · Cited by 901
Updated consensus statement on biological agents for the treatment of rheumatic diseases, 2010
Furst, D. E., Keystone, E. C., Braun, J., Breedveld, F. C., Burmester, G. R., De Benedetti, F., Dörner, T., Emery, P., Fleischmann, R., Gibofsky, A., et al. (2011) · Annals of the Rheumatic Diseases · doi:10.1136/ard.2010.146852 · Cited by 687
Galgiani, J. N., Ampel, N. M., Blair, J. E., Catanzaro, A., Geertsma, F., Hoover, S. E., Johnson, R. H., Kusne, S., Lisse, J., MacDonald, J. D., et al. (2016) · Clinical Infectious Diseases · doi:10.1093/cid/ciw360 · Cited by 622
Self-citationLimper, A. H., Knox, K. S., Sarosi, G. A., Ampel, N. M., Bennett, J. E., Catanzaro, A., Davies, S. F., Dismukes, W. E., Hage, C. A., Marr, K. A., et al. (2011) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.2008-740st · Cited by 612
Self-citationSalliot, C., Dougados, M., & Gossec, L. (2009) · Annals of the Rheumatic Diseases · doi:10.1136/ard.2007.083188 · Cited by 477
Metadata
- Authors
- Bergstrom, L., Yocum, D. E., Ampel, N. M., Villanueva, I., Lisse, J., Gluck, O., Tesser, J., Posever, J., Miller, M., Araujo, J., Kageyama, D. M., Berry, M., Karl, L., & Yung, C. M.
- Venue
- Arthritis & Rheumatism
- Publisher
- Wiley
- Published
- 2004-06
- Volume
- 50
- Issue
- 6
- Pages
- 1959-1966
- ISSN
- 0004-3591 (ISSN-L)
- 1529-0131
- OpenAlex
- W2052964479
- Cited by
- 268
- References
- 16
- FWCI
- 11.93
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Increased risk of coccidioidomycosis in patients treated with tumor necrosis factor α antagonists. https://app.cochat.ai/papers/10.1002/art.20454
- The paper
- Bergstrom, L., Yocum, D. E., Ampel, N. M., Villanueva, I., Lisse, J., Gluck, O., Tesser, J., Posever, J., Miller, M., Araujo, J., Kageyama, D. M., Berry, M., Karl, L., & Yung, C. M. (2004). Increased risk of coccidioidomycosis in patients treated with tumor necrosis factor α antagonists. Arthritis & Rheumatism. https://doi.org/10.1002/art.20454
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.